Prosecution Insights
Last updated: November 08, 2026
Application No. 19/106,043

CATION TRIGGERED LIPOSOMES

Non-Final OA §112
Filed
Feb 24, 2025
Priority
Aug 25, 2022 — provisional 63/400,881 +1 more
Examiner
DAVIS, BRIAN J
Art Unit
1614
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Toroid Pharmaceuticals LLC
OA Round
1 (Non-Final)
85%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
81%
With Interview

Examiner Intelligence

Grants 85% — above average
85%
Career Allowance Rate
1353 granted / 1595 resolved
+24.8% vs TC avg
Minimal -4% lift
Without
With
+-3.9%
Interview Lift
resolved cases with interview
Fast prosecutor
1y 9m
Avg Prosecution
45 currently pending
Career history
1643
Total Applications
across all art units

Statute-Specific Performance

§101
5.2%
-34.8% vs TC avg
§103
16.5%
-23.5% vs TC avg
§102
19.5%
-20.5% vs TC avg
§112
44.9%
+4.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1595 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Drawings The drawings are objected to because where only a single view is used in an application to illustrate the claimed invention, it must not be numbered and the abbreviation “FIG.” must not appear (37 CFR 1.84(u)(1)). Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as “amended.” If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either “Replacement Sheet” or “New Sheet” pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance. The examiner respectfully suggests the single drawing should be properly labeled: The Figure. Specification The disclosure is objected to because of the following informalities: as above, where only a single view is used in an application to illustrate the claimed invention, it must not be numbered and the abbreviation “FIG.” must not appear (37 CFR 1.84(u)(1)). That being the case, all references to the drawing in the specification should refer simply to: The Figure. Appropriate correction is required. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 8 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The claim contains the trademark/trade name “….DM-NitrophenTM….”. Note, however, that where a trademark or trade name is used in a claim as a limitation to describe a particular material or product, the claim does not comply with the requirements of 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph. In fact, the value of a trademark would be lost to the extent that it became the generic name of a product, rather than used as an identification of a source or origin of a product. Thus, the use of a trademark or trade name in a claim to describe a material or product would not only render a claim indefinite, but would also constitute an improper use of a trademark or trade name. (Note the discussion at MPEP 2173.05(u)). Claim 9 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. There is insufficient antecedent basis for the limitation “…the nanoscintillator is LuPO4…” in the claim. Claim 17 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. There is insufficient antecedent basis for the limitation “…said nanoscintillator…” in the claim. Claims 10, 11, 14 and 15 are also rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 10, 11, 14 and 15 all depend, or ultimately depend, from an indefinite claim yet do not relieve the indefiniteness. Dependent claims 10, 11, 14 and 15 are also, therefore, indefinite. Claim Rejections - 35 USC § 112(d) The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 5 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, fourth paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. In the present instance, the claim fails to further limit the claim upon which it depends. Claim 5, which ultimately depends from independent claim 1, merely repeats the limitation of claim 1 with respect to the therapeutic agent being entrapped in the lumen or within the lipid bilayer of the liposome. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Allowable Subject Matter Claims 1-4, 6, 7, 12, 13 and 16 are allowed. The subject matter of the remaining claims would be allowable once the 112 rejections outlined above have been overcome. The closest prior art appears to be an abstract from the 2019 Spring ACS meeting, pages COLL-0202, and which not being immediately accessible, its corresponding SciFinder abstract has been relied upon for purposes of this Office Action. (The original ACS abstract has been requested from the USPTO’s Scientific and Technical Information Center (STIC) and will be made of record as soon as available.) The reference teaches a strategy for the calcium-triggered release of liposome contents utilized as a means of drug delivery. A switchable lipid, sensitized to calcium, was synthesized and incorporated into liposomes. The calcium binding head group of this lipid acts as a trigger which upon calcium binding, driven by increased calcium concentration at target sites, induces a conformational change that perturbs the liposome membrane integrity and thereby causes content release. The reference does not teach, show, suggest or make obvious the instant (caged cation and cation responsive membrane permeabilizing lipid) liposome or its method of use. Conclusion The prior art made of record and not relied upon is considered pertinent to applicant's disclosure: ACS Nano (2011), 5(5), pp. 3961-3969 is cited as an example of a related liposome encapsulated-drug release strategy, which is a pH and temperature-sensitive drug release polymer network that surrounds a nanoscale drug-encapsulating liposome and functions as a drug release mechanism under appropriate conditions. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRIAN J DAVIS whose telephone number is (571)272-0638. The examiner can normally be reached M-F 8:30-5:00 PM EDT. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Ali Soroush, can be reached at 571-272-9925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRIAN J DAVIS/Primary Examiner, Art Unit 1614 9/10/2026
Read full office action

Prosecution Timeline

Feb 24, 2025
Application Filed
Sep 15, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778906
PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MUSCULAR WEAKNESS-RELATED DISEASES COMPRISING ALVERINE, 4-HYDROXY ALVERINE, DERIVATIVE THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
4y 0m to grant Granted Nov 03, 2026
Patent 12758498
A TOPICAL GEL FORMULATION FOR SKIN AND MOUTH DISORDERS AND A PROCESS OF PREPARATION THEREOF
2y 3m to grant Granted Oct 13, 2026
Patent 12751936
BENZENESULFONAMIDE DERIVATIVES AND METHOD FOR TREATING CANCER
7y 3m to grant Granted Oct 06, 2026
Patent 12747253
KRAS G12D INHIBITORS
3y 8m to grant Granted Sep 29, 2026
Patent 12746193
COSMETIC COMPOSITION
2y 9m to grant Granted Sep 29, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
85%
Grant Probability
81%
With Interview (-3.9%)
1y 9m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1595 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month